Atlas FDA

iStent inject® Trabecular Micro-Bypass System Model

FDA premarket approval P170043/S012 · decided 2022-02-18

Approval details

PMA number
P170043
Supplement
S012
Supplement type
30-Day Notice
Supplement reason
Process Change - Manufacturer/Sterilizer/Packager/Supplier
Trade name
iStent inject® Trabecular Micro-Bypass System Model
Generic name
Intraocular pressure lowering implant
Applicant
Glaukos Corporation
Date received
2022-02-04
Decision date
2022-02-18
Days to decision
14 days
Decision code
OK30
Product code
OGO
Advisory committee
Ophthalmic
Expedited review
No
Location
San Clemente, CA
Statement
Change to the sampling plan for Limulus Amebocyte Lysate (LAL) endotoxin testing.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
iStent infinite Trabecular Micro-Bypass System, Model iS3 (K220032)Glaukos Corporation2022-08-02